Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay.
Established treatments for psoriasis are generally based on antiproliferative, anti-inflammatory, or differentiation-modifying activity, or a combination of these effects. New agents for the treatment of psoriasis could be identified by high-throughput screening (HTS) of large compound libraries using keratinocyte proliferation models. Although several new proliferation assays have been developed, the radioactive [(3)H]-thymidine incorporation assay is still considered to be the gold standard for the evaluation of keratinocyte proliferation in vitro. In this study, we compare a number of simple, and reliable, colorimetric (MTT, NRU, SRB, and CVS), and fluorimetric (CAM and AB) methods with the [(3)H]-thymidine incorporation assay for the measurement of keratinocyte proliferation in the exponential growth phase in 96-well formats. The concentrations that induced 50% growth inhibition (GI(50)) were determined by each assay for the established antipsoriatics, dithranol, and methotrexate. Strong correlations were observed between the percentage growth inhibitions determined by the radioactive and the colorimetric assays, with no significant differences (P > 0.05) between their GI(50) values. The colorimetric assays are thus suitable alternatives to the radioactive assay for quantifying keratinocyte growth inhibition. We have also validated the use of the HaCaT cell line as a representative of the hyperproliferative psoriatic epidermis, in the preclinical screening of experimental anti-psoriatic agents.
George
Suja Elizabeth
SE
Sunderland Pharmacy School, University of Sunderland, Wharncliffe Street, Sunderland, United Kingdom.
Anderson
Rosaleen J
RJ
Cunningham
Anne
A
Donaldson
Michael
M
Groundwater
Paul W
PW
D000875:Anthralin / Q000494:pharmacology; D000891:Anti-Infective Agents, Local / Q000494:pharmacology; D053148:Caspase 3 / Q000378:metabolism; D053179:Caspase 7 / Q000378:metabolism; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects*; D003124:Colorimetry; D003879:Dermatologic Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005456:Fluorescent Dyes; D005470:Fluorometry; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects; D008727:Methotrexate / Q000494:pharmacology; D011565:Psoriasis / Q000188:drug therapy*; D015203:Reproducibility of Results; D013778:Tetrazolium Salts; D013844:Thiazoles; D013936:Thymidine / Q000378:metabolism*
D000891:Anti-Infective Agents, Local; D003879:Dermatologic Agents; D005456:Fluorescent Dyes; D013778:Tetrazolium Salts; D013844:Thiazoles; D053148:Caspase 3; D053179:Caspase 7; C022616:thiazolyl blue; D000875:Anthralin; D013936:Thymidine; D008727:Methotrexate